-+ 0.00%
-+ 0.00%
-+ 0.00%

Digel Pharmaceuticals (688192.SH): License agreement with AstraZeneca for Schwarzer® comes into effect

Zhitongcaijing·09/01/2026 00:49:02
Listen to the news

Zhitong Financial App News, Dizhe Pharmaceutical (688192.SH) issued an announcement. The company signed a “License Agreement” with AstraZeneca UK Limited (hereinafter referred to as “AstraZeneca”) on July 14, 2026, granting AstraZeneca the exclusive right to develop and commercialize Schwarzer® on a global scale. All the conditions for entry into force of the agreement agreed in the agreement have been met, and the agreement officially entered into force on August 31, 2026. AstraZeneca will commercialize Schwarzer® in the US in the fourth quarter of this year.

The company will receive a one-time, non-refundable down payment of $600 million from AstraZeneca, a clinical development milestone of up to $400 million, and a sales milestone payment of up to $500 million. In addition, the company will receive royalties based on a tiered ratio of the highest to the lowest double digit of Schwarzer® global sales.